5-Amino-1MQ

Small molecule · Metabolism & GLP-1

Not a peptide. Studied preclinically in fat-cell and energy metabolism; robust human efficacy and safety data are lacking.

Not FDA/EMA approved

LibraryNo account · this device only

Also known as: 5-amino-1-methylquinolinium · NNMT inhibitor

Use at a glance

5-Amino-1MQ

Not a peptide. Studied preclinically in fat-cell and energy metabolism; robust human efficacy and safety data are lacking.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?: 50 mg
How often?: once per day
What time of day?: morning
What period?: Week 1–2 · oral

How is it used?: Studies or online reports describe particular uses. They do not establish a general instruction for vendor products.
Does it need mixing?: No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

View preparation Check sources

Overview of all entries

5-Amino-1MQ · Week 1–2 · oral
Online report · not medically verified
50 mg · once per day · morning
5-Amino-1MQ · Week 3+ · oral
Online report · not medically verified
100–150 mg · once per day · morning
5-Amino-1MQ · Day 1–2 · subcutaneous
Online report · not medically verified
2.5 mg · once per day · not reliably established
5-Amino-1MQ · Day 3+ · subcutaneous
Online report · not medically verified
2.5–5 mg · 1–2 times per day · not reliably established
5-Amino-1MQ · pause
Online report · not medically verified
— · 4–6 weeks · not reliably established

More factsSmall molecule · Metabolism & GLP-1

Classification: Small molecule · Metabolism & GLP-1
Research focus: Not a peptide. Studied preclinically in fat-cell and energy metabolism; robust human efficacy and safety data are lacking.
Evidence: Preclinical
Status: Not FDA/EMA approved

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

Community source, oral: 50 mg in the morning during weeks 1–2, then usually 100 mg, with an upper online figure of 150 mg; subcutaneous anecdotes of 2.5–5 mg daily. No human dose is documented; not a peptide.

Profile evidence level: preclinical.

Timing

Oral in the morning, or split between morning/midday; subcutaneous claims are purely anecdotal.

No individual recommendation.

Cycle/duration

Community cycles of 8–12 weeks with a 4–6 week break; no clinically tested duration.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

No validated recipe is established for arbitrary research vials. The calculator shows concentration, not suitability or shelf life.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

50 mg · assumed final volume: 3 ml

Community calculation example

Calculated amount2.5 mg

Concentration16,666.67 µg/ml

U-10015 U

Volume0.15 ml

Calculated amount5 mg

Concentration16,666.67 µg/ml

U-10030 U

Volume0.3 ml

10 mg · assumed final volume: 1 ml

Community calculation example

Calculated amount2.5 mg

Concentration10,000 µg/ml

U-10025 U

Volume0.25 ml

Calculated amount5 mg

Concentration10,000 µg/ml

U-10050 U

Volume0.5 ml

All preparation informationProduct details and calculation examples from the available sources.

Community arithmetic, not a recommendation: 50 mg +3 ml →2.5 mg =15 U, 5 mg =30 U; alternatively 10 mg +1 ml →2.5 mg =25 U, 5 mg =50 U. There is no validated vial reconstitution or human efficacy.

Reconstitution & quantitiesOpen basics, units and sources

Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Experimental small-molecule inhibitor of nicotinamide N-methyltransferase

5-Amino-1MQ is classified as “Experimental small-molecule inhibitor of nicotinamide N-methyltransferase”. Not a peptide. Studied preclinically in fat-cell and energy metabolism; robust human efficacy and safety data are lacking. This describes the investigated pathway but does not validate a community use, amount, route or combination.

NNMT inhibition

This studies how inhibiting a metabolic enzyme called NNMT could affect the energy expenditure of fat cells, similar to removing a brake block. Enzyme activity and metabolic markers are measured in cell models.

Adipocyte metabolism

This studies how fat cells store, release, and burn energy, similar to observing how a storage tank fills and empties. Researchers typically measure fat cell size, enzyme activity, and energy expenditure in cell or animal models.

Cellular energy metabolism

Researchers study how cells produce and use energy, particularly through the mitochondria, similar to measuring how efficiently an engine burns fuel. Typical measures include oxygen consumption and energy output in cell models.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Weight management forums

In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.

Biohacker and longevity forums

Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.

Source and purity discussion

Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.

Adverse effects and safety risks

Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclinical

Robust human efficacy and safety have not been demonstrated.

Clinical evidence

Available data come mostly from animal or cell models; robust human efficacy and safety data are lacking.

5-Amino-1MQ is not a peptide but a small-molecule NNMT inhibitor, unlike peptide-based metabolic candidates.

Storage and stability

The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Comparison with related substances

Combinations / stacks

Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Sources and evidence hierarchy

Primary sources and official registries take priority. The community reference is labelled separately.

Database / searchPubMed: 5-amino-1MQ literature search
Primary sourceFDA — GenoGenix warning letter (5-Amino-1MQ)
Community reference5-Amino-1MQ — Peptide Dosing Protocols

Back to all 64 profiles Open scientific atlas profile